PositiveID Acquires MFSI to Bring Sample Prep, MDx Tech to Biodefense, Clinical Markets

The deal, worth as much as $8.2 million, is expected to enable the medical-tech firm to expand into the biodefense and clinical diagnostics markets via MFSI's multiplexed molecular assays and automated, PCR-based sample-to-answer technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.